Angiotensin type 2 receptor antagonism as a new target to manage gout (2022)
Source: Inflammopharmacology. Unidade: FMRP
Subjects: DOR, FARMACOTERAPIA, ANGIOTENSINA II, ANTI-INFLAMATÓRIOS, ANTIOXIDANTES, ARTRITE, ÁCIDO ÚRICO
ABNT
VIEIRA, Thiago Neves et al. Angiotensin type 2 receptor antagonism as a new target to manage gout. Inflammopharmacology, v. 30, n. 6, p. 2399-2410, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10787-022-01076-x. Acesso em: 09 set. 2024.APA
Vieira, T. N., Saraiva, A. L. L., Guimarães, R. M., Luiz, J. P. M., Pinto, L. G., Ávila, V. de M. R., et al. (2022). Angiotensin type 2 receptor antagonism as a new target to manage gout. Inflammopharmacology, 30( 6), 2399-2410. doi:10.1007/s10787-022-01076-xNLM
Vieira TN, Saraiva ALL, Guimarães RM, Luiz JPM, Pinto LG, Ávila V de MR, Goulart LR, Cunha Júnior JP, McNaughton PA, Cunha TM, Ferreira J, Silva CR. Angiotensin type 2 receptor antagonism as a new target to manage gout [Internet]. Inflammopharmacology. 2022 ; 30( 6): 2399-2410.[citado 2024 set. 09 ] Available from: https://doi.org/10.1007/s10787-022-01076-xVancouver
Vieira TN, Saraiva ALL, Guimarães RM, Luiz JPM, Pinto LG, Ávila V de MR, Goulart LR, Cunha Júnior JP, McNaughton PA, Cunha TM, Ferreira J, Silva CR. Angiotensin type 2 receptor antagonism as a new target to manage gout [Internet]. Inflammopharmacology. 2022 ; 30( 6): 2399-2410.[citado 2024 set. 09 ] Available from: https://doi.org/10.1007/s10787-022-01076-x